BI Asset Management Fondsmaeglerselskab A S Has $28.77 Million Stake in IDEXX Laboratories, Inc. $IDXX

BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 65.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,029 shares of the company’s stock after purchasing an additional 17,848 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned about 0.06% of IDEXX Laboratories worth $28,769,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in IDXX. STF Management LP grew its position in IDEXX Laboratories by 1.3% during the second quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after buying an additional 16 shares in the last quarter. Clearstead Trust LLC lifted its position in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after acquiring an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in shares of IDEXX Laboratories by 4.4% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after purchasing an additional 16 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in shares of IDEXX Laboratories by 3.3% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after purchasing an additional 17 shares in the last quarter. Finally, Stratos Wealth Partners LTD. increased its position in shares of IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after purchasing an additional 18 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

IDXX has been the subject of several recent analyst reports. BTIG Research cut their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Jefferies Financial Group reissued a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research note on Monday, November 3rd. Finally, Morgan Stanley raised their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $642.94 on Thursday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.87. The company has a market cap of $51.34 billion, a price-to-earnings ratio of 49.19, a PEG ratio of 3.86 and a beta of 1.67. The firm has a 50 day simple moving average of $698.15 and a 200 day simple moving average of $663.33.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business earned $2.53 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.